Syncona
@SynconaLtd
Followers
679
Following
175
Statuses
299
Creating, Building and Scaling a portfolio of global leaders in life science
London, England
Joined February 2019
This week we were pleased to announce the official opening of our new office at 8 Bloomsbury Street by Baroness Manningham-Buller, Chair of the Wellcome Trust #Syncona
0
0
6
Today Syncona today announced its Third Quarter Update covering the period from 01 October to 31 December 2024. To see the full release, please click here:
0
0
1
Today Syncona announced its Half Year Results. Management will be delivering a presentation followed by a Q&A session which begins at 9am this morning. To register for the webcast, and to see the full release, please click the link below:
0
0
0
Today we announced our first quarter update, highlighting strong clinical execution from a rebalanced and diversified portfolio that continues to attract significant external capital. Read the full announcement here:
0
0
1
Today Syncona announces its Annual Results for the 12-month period ending 31 March 2024. Management will be delivering a presentation followed by a question and answer session which begins at 9am this morning. To register, and to see the full release:
0
0
2
Syncona was pleased to recently welcome two senior leaders to the business in, Executive Partner, John Tsai, and Managing Partner, Roel Bulthuis. Here they discuss their experience, what attracted them to Syncona, and their priorities since joining.
0
0
1
Autolus Therapeutics announced it has submitted its Biologics License Application to the US #FDA for obe-cel for patients with relapsed/refractory adult B-Cell Acute Lymphoblastic #Leukaemia. Read the full announcement here: #biotech #celltherapy
0
0
5
Syncona is pleased to announce its Interim Results for the 6-month period ending 30 September 2023. To read the full announcement, please visit the following link:
0
0
1
We’ve released our Q1 update, highlighting the continued progress across our maturing portfolio. Our portfolio companies continue to deliver on their clinical and operational plans as our late-stage clinical companies approach important milestones:
1
0
2
“Simply being the first mover against a given target won’t be enough”, Syncona CEO Chris Hollowood shares his perspective on the future of the scientific landscape. Find out more about current opportunities in the blog: #lifescience #pharma #blog
0
0
1
Strategy Director at Syncona portfolio company OMass Therapeutics @omasstx, Miguel Campos Silva, speaks about OMass’ #sustainability journey and Syncona’s active involvement. Read the full Q&A with Miguel here: #lifescience
1
1
4
Today @FreelineLife announced it has dosed its first patient with its novel adeno-associated virus (#AAV) #genetherapy candidate for #Gaucher disease, marking an important step forward for the Gaucher community. Read the full announcement here:
0
0
2
Today Syncona announces its Preliminary Results for the 12-month period ending 31 March 2023. Management will be delivering a presentation followed by a Q&A session which begins at 9am. To register for the webcast, and to see the full release, click below:
0
0
1
This week not only did we launch our new brand but we launched Beacon Therapeutics, a new leading ophthalmic gene therapy company. Watch the full video on Beacon’s launch here: #ophthalmology
0
0
0
Following today’s launch of Beacon Therapeutics, a new leading ophthalmic gene therapy company, please visit our new refreshed website to find out more about the company. Watch the full video on Beacon’s launch here:
0
0
1
We’re excited to launch a leading ophthalmic gene therapy company Beacon Therapeutics with £96 million Series A financing by combining AGTC’s late-stage X-linked retinitis pigmentosa (XLRP) programme with two proprietary pre-clinical programmes. More here:
1
2
4
Syncona is pleased to announce that its portfolio company Quell has entered into a collaboration, exclusive option and license agreement with @AstraZeneca, in which Quell will receive $85 million upfront from AstraZeneca. Read more here:
0
0
3
Syncona CEO Chris Hollowood has been quoted in today's @thetimes, having spoken to @alexralph about the opportunities and challenges facing biotechs in the UK. #UKbiotech #opportunities
0
0
0
RT @michelledonelan: #ICYMI the sale of Silicon Valley Bank UK @SVB_UK to @HSBC over the weekend will safeguard thousands of British jobs,…
0
13
0
Read Syncona CEO Chris Hollowood reflect on the current state of the biotech sector and what's next for Syncona:
0
0
1
RT @OxEngage: Today is @rarediseaseday. Read how @omasstx, is using new technologies to develop treatments for rare immunological and genet…
0
3
0